Abstract: Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided.

Abstract: The present invention relates to efflux inhibitor compounds, compositions, and methods of using the same. More specifically, the instant invention comprises deuterated analogs of elacridar with superior pharmacokinetic properties such that it is now possible to facilitate accumulation and distribution of therapeutic agents to effective levels in cells or compartments protected by efflux transporter proteins such as Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-GP). Such transporter protected compartments include brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeballs, retina, inner ear, placenta, mammary gland, liver, biliary tract, kidney, intestines, lung, adrenal cortex, endometrium, hematopoietic cells, stem cells, and solid tumors. In other embodiments, the present invention comprises methods of using the instant deuterated analogs.

Abstract: An injectable lipid-based suspension of buprenorphine providing one to seven days of pain alleviation has been developed. A method of manufacturing an injectable buprenorphine formulation providing about two to three days of pain therapy has been developed. A method of manufacturing an injectable buprenorphine formulation providing about one to seven, preferably two to three, days of pain therapy has been developed. The formulation is made by mixing buprenorphine, glyceryl distearate, and glyceryl tristearate dry powers with a liquid medium chain triglyceride (MCT), such as MIGLYOL® 812. The buprenorphine-Glycerol di and tristearate (Bup-GDS-GTS) is provided in a range of 0.2 to 20 mg Bup-GDS-GTS to one ml (gram) MCT.

Abstract: A controlled release formulation comprising an opioid growth factor receptor (OGFR) antagonist and at least one pharmaceutically acceptable carrier has been developed, which is useful for treating cancer when locally administered at a disease site.

Abstract: Synergistic drug combinations with the small molecule PAC-1 against uveal or cutaneous melanoma. There are no current targeted drug treatments for the mutations associated with uveal melanoma. Despite primary radiation or surgical therapy, up to 50% of patients eventually develop metastatic disease, for which there is no standard therapy nor treatment shown to improve overall survival. Drug combinations with PAC-1 allow the use of lower dosages of this compound that result in cancer cell death in uveal melanoma. Drug combinations of PAC-1 with the kinase inhibitor entrectinib have shown a synergistic effect against uveal melanoma cell lines. Specifically, PAC-1 and entrectinib are synergistic against wild-type and mutant uveal melanoma cell lines (e.g., GNAQ and GNA11).

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.

Abstract: Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.

Abstract: The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.

Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: The invention relates to pharmaceutical compositions comprising ((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)oxy)methyl pivalate or a pharmaceutically acceptable derivative thereof, optionally with an additional agent, methods of making them, and their use in medicine.

Abstract: Disclosed are methods of treating cystic fibrosis using AmB and a sterol or compositions comprising AmB and a sterol. Also disclosed are methods of increasing the pH of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol; and methods of decreasing the viscosity of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol.

Abstract: The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human mammalian subject by administering to the subject by intramammary infusion an agent which activate the OAS2 signalling pathway or induce expression of OAS2. In some examples, the methods and reagents of the disclosure may be useful for the prevention of mastitis in a non-human mammalian subject, such as a dairy cow.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, a quasi-drug composition for preventing or improving dentin-dental pulp disease or periodontal disease or a health functional food composition for preventing or improving dentin-dental pulp disease or periodontal disease, all of which comprise a LPAR2 (lysophosphatidic acid receptor 2) inhibitor.

Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.

Abstract: Compositions, e.g., pharmaceutical compositions, nutritional compositions, medical foods, and food ingredients, as well as their methods of use, are provided, for treating diseases associated with hyperammonemia, e.g., urea cycle disorders (UCD) and hepatic encephalopathy (HE), e.g., minimal HE (MHE) and overt HE (OHE), and modulating enzyme activities and levels of microbes and taxa, and metabolites (e.g., ammonia) in the microbiome of a subject.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: Methods are provided for treating a subject for glioblastoma, including e.g., an EGFRvIII negative glioblastoma. The methods of the present disclosure involve administering to a subject a molecular circuit that includes a binding triggered transcriptional switch (BTTS) that binds to a priming antigen expressed by the subjects glioblastoma multiforme (GBM) that, when bound to the priming antigen, induces one or more encoded therapeutics specific for one or more antigens expressed by the GBM. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.

Abstract: A cell preparation for treating brain tumors used in combination with a prodrug that is converted to 5-fluorouracil by cytosine deaminase, wherein the cell preparation comprises neural stem cells derived from pluripotent stem cells having a cytosine deaminase gene and a uracil phosphoribosyltransferase gene is provided to establish new means for treating brain tumors.

Abstract: Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

Abstract: Disclosed are compositions and methods of treating muscular dystrophies, including Duchenne Muscular Dystrophy (DMD) through administration of fibroblasts and modified fibroblasts systemically and locally. In certain embodiments, fibroblast cells are utilized for replacement of dystrophin through fusion and/or other means of horizontal gene transfer. In other embodiments, the disclosure teaches the use of fibroblasts for reduction of inflammatory reactions and/or immunological reactions which propagate and enhance myodestructive aspects of Duchenne Muscular Dystrophy. In other embodiments, fibroblasts are utilized as vectors for gene therapy and/or gene modifications approaches.

Abstract: Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided.

Abstract: Disclosed is therapeutic use of an extract from rabbit skin inflamed by vaccinia virus. Particularly, disclosed is use of an extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage or pancytopenia induced by an anti-cancer therapy. Moreover, disclosed is use of an extract from rabbit skin inflamed by vaccinia virus in treating leukopenia induced by an anti-cancer therapy. Further, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

Abstract: A method for modifying gene expression of diseased cells in a patient including preparing an extract of diseased cells, forming a plurality of conditioned stem cells by treating a plurality of normal stem cells with a solution of the extract of the diseased cells with a volume ratio between 10?15 volume/volume (v/v) and 10?3 v/v (volume of the extract of the diseased cells/volume of a culture medium), forming a conditioned stem cell-derived extract, and forming a plurality of healthy cells by treating the diseased cells with the conditioned stem cell-derived extract.

Abstract: Methods of making mixed allergen compositions, e.g., substantially aerobic organism free mixed allergen compositions, and the resulting allergen composition, are provided.

Abstract: A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.

Abstract: Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.

Abstract: Disclosed herein is a method for preventing or alleviating particulate matter-induced lung injury. The method includes administering to a subject in need thereof a pharmaceutical composition including at least one heat-killed lactic acid bacterial strain that is selected from the group consisting of Lactobacillus plantarum CB102 which is deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 33894, Lactobacillus acidophilus JCM 1132, Bifidobacterium longum CB108 which is deposited at the DSMZ GmbH under an accession number DSM 33895, Bifidobacterium animalis subsp. lactis JCM 10602, and combinations thereof.

Abstract: The present invention provides methods for treating an individual having bladder cancer, the methods comprising intravesical administration of an oncolytic virus and intravenously administering an anti-PD-1 antibody.

Abstract: A traditional Chinese medicine composition for treating dermatophytosis and bromhidrosis, which is prepared from radix sophorae flavescentis and peristrophe japonica, has synergistic interaction and anti-fungal effects, and is not easy to produce drug tolerance. After performing compatibility of extracts of matrine and peristrophe japonica, dermatophytosis and bromhidrosis can be treated, and multiple external preparations can be prepared.

Abstract: Some variations provide a process of converting a cannabinoid into a purified cannabinoid derivative, comprising: providing a starting composition comprising a cannabinoid; providing a C9-C11 non-aromatic hydrocarbon solvent; introducing the starting composition and the solvent to a conversion reactor; chemically converting some, but not all, of the cannabinoid to a cannabinoid derivative, generating a reaction mixture containing unreacted cannabinoid; conveying the reaction mixture to a crystallization unit; cooling the reaction mixture to precipitate unreacted cannabinoid out of the reaction mixture, thereby generating a mother liquor containing the cannabinoid derivative; and isolating and recovering the cannabinoid derivative from the mother liquor. Systems configured to carry out the disclosed processes are also provided. This invention offers a large-scale solution to economically convert CBD to D9-THC, among many other example.

Abstract: The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

Abstract: The present application relates to use for anti-inflammation, and/or for prevention, improvement, and/or treatment of diseases related to vascular dysfunction of Java pepper extract, and provides a composition with an excellent anti-inflammatory effect and/or an excellent effect of prevention, improvement, and/or treatment of diseases related to vascular dysfunction, which is excellent in biosafety, by comprising Java pepper extract.

Abstract: Nutritional supplement compositions are disclosed for improving health and function of the gut-brain-axis (GBX) and one or more mood states (MS) of an individual—also described as Mental Wellness (MW). Nutritional supplements disclosed herein may include plant material from any combination of (1) pine bark, (2) grape seed, and (3) apple fruit and peel. Related processes are also disclosed.

Abstract: Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.

Abstract: Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

Abstract: An application of a RyR2 protein or a recombinant RyR2 protein in preparing an anti-heart failure medicament is provided. The recombinant RyR2 protein is a naturally occurring RyR2 protein fragment or a mutant, such as a SPRY1 domain protein, a P1 domain protein, a SPRY2 domain protein, a SPRY3 domain protein, a Handle domain protein, an HD1 domain protein, an HD2 domain protein, a central domain protein, an EF-hand domain protein, a U-motif protein, a P2 domain protein, a P2 domain fragment protein-1, a P2 domain fragment protein-2 derived from a natural RyR2 protein or a P2 mutant derived from the natural RyR2 protein. The exogenous recombinant RyR2 protein is highly expressed in both normal small animal and diseased small animal models, so that the left ventricular ejection fraction of experimental animals is improved varying degrees compared with that of a control group.

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Abstract: The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a T cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (IL-2cx), (e) a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating t

Abstract: The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

Abstract: The invention relates to a trypanosomal vaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent trypanosomal infection in a mammal.

Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.

Abstract: The present embodiments provide for a Mycobacterium tuberculosis (M. tuberculosis) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one M. tuberculosis peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Mycobacterium tuberculosis, Type 5 (CP5) or Type 8 (CP8), or a combination of Type 5 or Type 8 capsular polysaccharide from Staphylococcus aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide M. tuberculosis antigens are indirectly linked via an affinity binding pair. The present M. tuberculosis-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple M. tuberculosis antigens at the same time.

Abstract: The present invention relates to an mammalian non-pathogenic, highly-productive-in-embryonated-egg, heat-resistant, and attenuated clade 2.3.4.4c H5N6 recombinant influenza A virus, and a vaccine composition including the recombinant influenza virus and artificial H5 gene as active ingredients.